ORAMED PHARMACEUTICALS INC. — Form SCHEDULE 13D/A
Filed July 22, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
This is an amended Schedule 13D/A filing dated July 22, 2026, relating to Oramed Pharmaceuticals Inc. (market value ~$77.7M). The filing references Nano Dimension Ltd. as the subject company. However, the document header does not disclose the specific beneficial ownership stake, share count, percentage owned, or what changed from the prior filing. Without the actual amendment details, the substance of the disclosure cannot be determined.
Why this rating
Schedule 13D amendments are routine regulatory filings. Significance cannot be assessed without disclosure of actual ownership %, shares, or material changes. Likely administrative update.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.